Sirtratumab vedotin
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1].
Product Specifications
CAS Number
1824663-83-3
Product Name Alternative
AGS15E; ASG-15ME; 1vcMMAE
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs)
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
96.42
Solubility
H2O
Smiles
[Sirtratumabvedotin]
References & Citations
[1]Morrison K, et al. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15 (6) :1301-10.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K4952307 1.0 µg DNA
Cox15 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)
Sign In for Pricing
View Details 
MBS013530-01 48 Well
Canine Serine/Threonine-Protein Kinase GSK3A (GSK3A)
Sign In for Pricing
View Details MBS013530-02 96 Well
Canine Serine/Threonine-Protein Kinase GSK3A (GSK3A)
Sign In for Pricing
View Details